Our News
January 12, 2025
Alnylam’s Chief Scientific Officer Kevin Fitzgerald, PhD, recently spoke with journalist Luke Timmerman on The Long Run podcast. The conversation covered the past, present and future of RNAi therapeutics as well as Kevin’s career journey. Find out what it took to turn a kid without a strong sense of direction into a biotech leader determined to harness a revolution in biology for human health. And learn how the Alnylam team managed to overcome challenge after challenge to deliver RNAi therapeutics to target cells and create a transformative class of medicines that’s poised to help many additional patients with rare and common diseases.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site